John Lawrence Hays MD

Gastrointestinal Cancer, Gynecologic Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Division of Medical Oncology, Ohio State University College of Medicine

2050 Kenny RdTower 8th FloorColumbus, OH 43221
Phone+1 614-293-6529
Fax+1 614-293-9469

Dr. Hays is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hays' full profile Already have an account?

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 2005 - 2008
University of Texas Medical Branch School of MedicineClass of 2005

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2012 - 2026
MD State Medical License 2008 - 2012
NC State Medical License 2005 - 2008

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017

Clinical Trials

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Start of enrollment: 2014 May 20
ACTIVE_NOT_RECRUITING
PHASE1
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2018 Oct 25
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian...
Laura M Chambers, Daniel Spakowicz, Julia Chalif, Reed O'Connor, Quinn Kistenfeger
Gynecologic Oncology. 2026-06-27
Risk Stratification and Contemporary Predictors of Survival in Hepatocellular Carcinoma Treated With Transarterial Radioembolization.
Deepak Sherpally, Parthib Das, Fode Tounkara, Khalid Mumtaz, Mina S Makary
Gastroenterology Research. 2025-10-01
2 citations
Prevalence of cannabis and medication use by indices of residential urbanicity and deprivation among Ohio cancer patients.
Theodore M Brasky, Shieun Lee, Bella McBride, Alison M Newton, Ryan D Baltic
Cancer Causes & Control. 2025-07-01

Journal Articles

The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources
James L Chen, John L Hays, Yearbook of Medical Informatics
Loss of TXNIP Enhances Peritoneal Metastasis and Can Be Abrogated by Dual TORC1/2 Inhibition
David Cohen, James L Chen, John L Hays, Oncotarget
Early closure for safety: A phase II clinical trial of polyethylene glycol conjugated L-asparaginase in patients with advanced ovarian cancer
6. Hays, J.L., Kim, G., Annunziata, C.M., Lee, J-m. Squires, J., Houston, N., and Kohn, E.C., Molecular and Clinical Oncology, 3/20/2013

Press Mentions

Dr. Hays on Immunotherapy in Ovarian Cancer TreatmentJanuary 14th, 2020
Foundation DonationMarch 2nd, 2017
NCCN Awards Research Grants to Eight Investigators to Support Clinical and Pre-Clinical Studies of Mirvetuximab Soravtansine in Various CancersJune 6th, 2016